Praxis Precision Medicines(NASDAQ) PRAX

Praxis Precision Medicines NASDAQ:PRAX makes treatments for brain disorders. These medicines help stop seizures and involuntary shaking. The company focuses on patients with rare genetic conditions.

The Precision Medicine Toolkit

• Cerebrum Platform: Uses small molecules to create oral pills that adjust brain cell activity.
• Solidus Platform: Employs antisense oligonucleotides to target specific genetic causes of disease.
• Ulixacaltamide: Investigational drug for essential tremor, a condition causing involuntary shaking.
• Relutrigine: Oral treatment candidate for specific types of childhood epilepsy.
• Elsunersen: Targeted therapy for a rare genetic seizure disorder caused by specific gene variants.

Path to the Pharmacy

• Submitted a New Drug Application for ulixacaltamide to the FDA with a target action date of Jan. 29, 2027.
• Applied for FDA approval for relutrigine with an updated target action date of Dec. 27, 2026.
• Partnered with Remagine Labs in July 2026 to develop a wearable drug delivery patch.
• Completed a public offering in Jan. 2026 that generated approximately $621.2 million in net proceeds.
• Received breakthrough therapy designation from the FDA for elsunersen in June 2026.

A Virtual Approach to Discovery

Praxis utilizes a virtual research and development model, relying on external consultants, collaborators, and contract organizations to conduct its scientific activities. This strategy allows the firm to maintain a specialized internal team while accessing global expertise for drug manufacturing and clinical trials.

Checking the Balance Sheet

• Net loss was $176.3 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $1.4 billion as of June 30, 2026.
• Research and development expenses were $147.4 million for the six-month period ended June 30, 2026.
• Market cap reached $9.8 billion in Q2 2026, up 980.0% year over year.
• Accumulated deficit reached $1.3 billion as of June 30, 2026.

Ready for the Next Phase

Praxis has transitioned from early research toward potential commercial operations with multiple drugs awaiting regulatory decisions. Its dual-platform strategy targets both common movement disorders and rare genetic conditions.